Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study

Marc Rendell; Steven G. Chrysant

doi:10.3810/pgm.2011.07.2318

Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study

Marc Rendell, Steven G. Chrysant

Department of Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Original language	English (US)
Pages (from-to)	183-186
Number of pages	4
Journal	Postgraduate medicine
Volume	123
Issue number	4
DOIs	https://doi.org/10.3810/pgm.2011.07.2318
State	Published - Jul 2011

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.3810/pgm.2011.07.2318

Cite this

@article{73ce5b0043294948bb6e150db4e19759,

title = "Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study",

author = "Marc Rendell and Chrysant, {Steven G.}",

note = "Funding Information: This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI), including writing and editorial assistance provided by Tamsin Williamson and Envision Scientific Solutions (Southport, CT). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), were fully responsible for all content and editorial decisions, and were involved at all stages of manuscript development. The authors received no compensation for development of the manuscript.",

year = "2011",

month = jul,

doi = "10.3810/pgm.2011.07.2318",

language = "English (US)",

volume = "123",

pages = "183--186",

journal = "Postgraduate Medicine",

issn = "0032-5481",

publisher = "Medquest Communications LLC",

number = "4",

}

TY - JOUR

T1 - Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes

T2 - A randomized, double-blind, placebo-controlled study

AU - Rendell, Marc

AU - Chrysant, Steven G.

N1 - Funding Information: This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI), including writing and editorial assistance provided by Tamsin Williamson and Envision Scientific Solutions (Southport, CT). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), were fully responsible for all content and editorial decisions, and were involved at all stages of manuscript development. The authors received no compensation for development of the manuscript.

PY - 2011/7

Y1 - 2011/7

UR - http://www.scopus.com/inward/record.url?scp=79960320108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960320108&partnerID=8YFLogxK

U2 - 10.3810/pgm.2011.07.2318

DO - 10.3810/pgm.2011.07.2318

M3 - Article

C2 - 21681003

AN - SCOPUS:79960320108

VL - 123

SP - 183

EP - 186

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 4

ER -

Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this